http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 13 Aug 2024 07:30:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Press+Releases/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html <p>VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.<br/></p> <p>Under http://www.streetinsider.com/Globe+Newswire/Optimi+Health+and+Psyence+Biomedical+Sign+Non-Binding+Letter+of+Intent+to+Advance+Global+Psilocybin+Drug+Development/23589084.html Tue, 13 Aug 2024 07:30:00 -0500 8BN A.06822034 A.17150087 O.03270327 O.20026344 O.49223070 O.53098441 OPTHF OPTI PBM PSYG